ClinicalTrials.gg
RecruitingNCT07498426Updated Oct 15, 2026

A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

A Phase 3 interventional study of NIO752 and Placebo in Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS), sponsored by Novartis Pharmaceuticals. Recruiting at 64 sites in 12 countries. Open to participants aged 41 Years to 81 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 15, 2026First sites in Belgium and United Kingdom22 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
41 Years to 81 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Supranuclear Palsy, Progressive with a site in Germany — 4 open to participants now, 5 under way, 1 of them phase 3. Supranuclear Palsy, Progressive · Germany.

Planned enrollment
5th of 18
300 · median 67
Started
2026
the only one that year
Phase 3
3 of 21
1 open now
Registered
21st of 21
by date
Lead sponsor
2 of 21
Novartis Pharmaceuticals

Among the 21 studies in Supranuclear Palsy, Progressive with a site in Germany, this one is the 5th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2026, is one of 3 in phase 3, and was the 21st registered.

Supranuclear Palsy, Progressive

171 studies on the registry are indexed under Supranuclear Palsy, Progressive; 51 are open to participants now.

Browse Supranuclear Palsy, Progressive studies →

Open to participants now

4 of the 21 studies in Supranuclear Palsy, Progressive with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 38 Supranuclear Palsy, Progressive studies recruiting now, 22 (58%) set no upper age limit and 2 (5%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.

This study: 41 Years to 81 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Supranuclear Palsy, Progressive with a site in Germany, or all of them as a file.
02

Study summary

This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP). Eligible participants will be randomized to receive either NIO752 or placebo followed by an open-label extension.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, parallel group, study to evaluate the efficacy of NIO752 in participants with Progressive Supranuclear Palsy followed by an open-label extension (OLE).

The participants with or without symptomatic therapy will be randomly allocated to either NIO752 or placebo treatment in a 2:1 randomization ratio.

Upon completion of the core double-blind treatment period, participants will be offered to continue with NIO752 treatment in the OLE.

03

Conditions studied

  • Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)

Keywords

  • Progressive Supranuclear Palsy (PSP)
  • NIO752
  • Anti-Sense Oligonucleotide (ASO)
  • Microtubule Associated Protein Tau (MAPT)
04

Who can participate

Ages eligible
41 Years to 81 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed must be obtained prior to participation in the study.
  2. Male or female participants, age between 41-81 yrs inclusive.
  3. Diagnosis of mild-moderate, probable/possible PSP Richardson syndrome as per MDS-PSP 2017 criteria with symptoms onset \< 5 years.
  4. PSPRS total score less than 40 at Baseline.
  5. Reliable study partner such as spouse, sibling, close friend, or caregiver able and willing to provide accurate information (including clinical symptoms and medical history) about the participant and to participate in study visits and informant-based assessments for the duration of the study. A reliable study partner is expected to spend enough time (at least 5 hours per week) with the study participant.
  6. Participant is able to ambulate defined as the ability to take at least 10 steps independently or with minimal assistance (stabilization of one arm to minimize fall risk).
  7. (MMSE) score ≥ 20 at Screening.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of other significant neurological or psychiatric disorders including (but not limited to) Parkinsons' Disease (which has not subsequently been revised to a diagnosis of PSP); Alzheimer's disease (AD), dementia with Lewy bodies; prion disease; any psychotic disorders; severe Major depressive disorder; seizure; brain tumor or other space-occupying lesion; history of stroke (e.g., stroke with permanent neurological deficit); history of head injury with loss of consciousness for at least 15 minutes within the past 20 years.
  2. Diagnosis of amyotrophic lateral sclerosis or other motor neuron diseases.
  3. Diagnosis of cerebellar ataxia, choreoathetosis, and early symptomatic autonomic dysfunction.
  4. History of or screening brain MRI scan indicative of significant abnormality, including, but not limited to, prior hemorrhage or infarct >1 cm3, >3 lacunar infarcts, cerebral contusion, aneurysm, vascular malformation >1 cm3, subdural hematoma, hydrocephalus, and space-occupying lesion (e.g., abscess or brain tumor).
  5. to undergo MRI procedure, including metal (ferromagnetic) implants and/or a cardiac pacemaker that is not compatible with MRI.
  6. Medical conditions that would, as per Investigator's judgement, prevent the participant from undergoing lumbar puncture, including but not limited to:

    1. Known allergy to local anesthetic
    2. History of back surgery (with the exception of microdiscectomy or laminectomy over 1 level)
    3. Spinal deformities
    4. Current dermatological infection at the lumbar puncture spot and/or significant skin alterations at the planned puncture place
    5. Risk of increased or uncontrolled bleeding and/or risk of bleeding that if not managed optimally, could place a participant at an increased risk for procedural bleeding. These could include, but are not limited, to anatomical factors at or near the LP site (e.g., vascular abnormalities, neoplasms) and underlying disorders of coagulation, function or platelet count (e.g. abnormal coagulation parameters, hemophilia, Von Willebrand's disease, liver disease).
  7. History of deep brain stimulator surgery other than sham surgery for participation in a deep brain stimulation clinical trial.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    NIO752

    NIO752 solution

    Other: NIO752

  • Placebo comparator
    Placebo

    Placebo in solution

    Drug: Placebo

Interventions

  • OtherNIO752

    Solution of antisense oligonucleotide.

  • DrugPlacebo

    Placebo solution

06

What researchers measure

Primary outcomes

  1. Change from baseline in the mPSPRS-10 score

    The 10-item Progressive Supranuclear Palsy Rating Scale (mPSPRS-10) is a modified version of the original 28 item PSPRS developed to improve clinical meaningfulness and statistical performance. The 10 items measure three key motor domains: gait, limb function, and bulbar. The mPSPRS-10 ranges between 0 and 30, with higher scores indicating greater disability.

    Time frame: Baseline, Week 72

Secondary outcomes

  1. Change from baseline in the PSPRS-28 items score

    28-item Progressive Supranuclear Palsy Rating Scale (PSPRS-28) , scale ranges between 0 and 100 with higher scores indicating greater disability.

    Time frame: Baseline, Week 72

  2. Changes from baseline in activities of daily living on the Cortical Basal ganglia Functional Scale (CBFS)

    The CBFS is a patient/study partner reported rating scale designed to evaluate the functional impact of 4 repeat tauopathies (4RTs), including PSP. The level of disability assessed by the CBFS correlates with motor, cognitive and psychiatric impairments. The CBFS consists of 14 questions on Motor experiences in daily living (EDL's) and 17 questions on non-Motor EDL's, each rated on a Likert 5-point scale that goes from 0 (Normal/No problems) to 4 (Severe problems).

    Time frame: From baseline up to week 72

  3. Change from baseline on the PSP-ShoQoL

    The Progressive Supranuclear Palsy - Short version Quality of Life (PSP-ShoQoL) is a patient reported outcome that comprises 12 items, covering phyisical (7 items) and mental health (5 items) states. Items are scored from 0 (no problem) to 4 (extreme problems), total score ranges from 0 to 48 with higher scores indicating greater impact of the disease on the quality of life.

    Time frame: From baseline up to week 72

  4. Change from baseline in Category (or Semantic) Fluency test over time

    The Category Fluency test is a measure of semantic retrieval and executive functions. It requires the study participant to name as many objects as possible belonging to a given category within one minute. The total score is given by the number of correct words generated within the time limit.

    Time frame: From baseline up to week 72

  5. Change from baseline in Letter (or Phonemic) Fluency test over time

    The Letter Fluency test is a measure of language and executive functions. It requires the study participant to name as many words as possible starting with a certain letter within one minute. The total score is given by the number of correct words generated within the time limit.

    Time frame: From baseline up to week 72

  6. Change from baseline in Symbol Digit Modality Test (SDMT) over time

    The SDMT is a measure of attention and processing speed. It requires the study participant to orally pair specific numbers with symbols as quickly and as accurately as possible using a reference key.

    Time frame: From baseline up to week 72

  7. Change from baseline in Letter-Number Sequencing task (LNS) over time

    The LNS is a sub-test of the Weschler Adult Intelligence Scale - Fourth Edition (WAIS-IV) and it is a measure of working memory and executive function. The study participant is read a sequence of numbers and letters and is required to recall the numbers in ascending order followed by the letters in alphabetical order.

    Time frame: From baseline up to week 72

  8. Ratio to baseline of NfL (CSF)

    Neurofilament light chain (NfL) is a specific marker of neuroaxonal damage. NfL in CSF will be used to assess the effect of NIO752 on neurodegeneration.

    Time frame: From baseline up to week 72

  9. Ratio to baseline of CSF phospho-Tau-181 and CSF Total-Tau

    Ratio to baseline in Total -Tau and Phospho-Tau-181 will be used as measures of target engagement

    Time frame: From baseline up to week 72

  10. Changes from baseline in volumes of brain structures as measured by MRI

    MRI measured volumes will be collected for ventricles, whole brain, midbrain, pons, superior cerebellar peduncle, third ventricle and frontal lobe

    Time frame: From baseline up to week 72

  11. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Incidence and severity of AEs and SAEs by treatment group, including clinical laboratory evaluations, vital signs, ECG, C-SSRS qualifying and reported as AEs.

    Time frame: From first treatment administration up to 72 weeks

07

Study locations

64 of 64 sites recruiting
  • Mayo Clinic Arizona
    Scottsdale, Arizona 85259, United States
    Recruiting
    • Heather Esnaola · Contactesnaola.heather@mayo.edu · +1 480 301 8300
    • Erika D Driver-Dunckley · Principal investigator
  • Univ of California San Francisco
    San Francisco, California 94158, United States
    Recruiting
  • CenExcel Rocky Mtn Clin Research
    Englewood, Colorado 80113, United States
    Recruiting
    • Jessica Crall · Contactj.crall@cenexel.com · +1 303 762 6674
    • Meagen Salinas · Principal investigator
  • Parkinsons Disease and Movement Disorders Center of Boca Raton
    Boca Raton, Florida 33486, United States
    Recruiting
  • Mayo Jacksonville
    Jacksonville, Florida 32224, United States
    Recruiting
  • University of Kentucky - C201 Clinic
    Lexington, Kentucky 40536, United States
    Recruiting
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
    Recruiting
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Recruiting
  • Central TX Neuro Consultants P A
    Round Rock, Texas 78681, United States
    Recruiting
  • Novartis Investigative Site
    Kogarah, New South Wales 2217, Australia
    Recruiting
  • Novartis Investigative Site
    Westmead, New South Wales 2145, Australia
    Recruiting
  • Novartis Investigative Site
    Melbourne, Victoria 3004, Australia
    Recruiting
  • Novartis Investigative Site
    Leuven, Vlaams Brabant 3000, Belgium
    Recruiting
  • Novartis Investigative Site
    Bruges, 8000, Belgium
    Recruiting
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
    Recruiting
  • Novartis Investigative Site
    Beijing, 100034, China
    Recruiting
  • Novartis Investigative Site
    Beijing, 100730, China
    Recruiting
  • Novartis Investigative Site
    Jinan, 250012, China
    Recruiting
  • Novartis Investigative Site
    Shanghai, 200040, China
    Recruiting
  • Novartis Investigative Site
    Suzhou, 215000, China
    Recruiting
  • Novartis Investigative Site
    Wuhan, 430022, China
    Recruiting
  • Novartis Investigative Site
    Caen, 14033, France
    Recruiting
  • Novartis Investigative Site
    Créteil, 94010, France
    Recruiting
  • Novartis Investigative Site
    Lille, 59037, France
    Recruiting
  • Novartis Investigative Site
    Marseille, 13885, France
    Recruiting
  • Novartis Investigative Site
    Nantes, 44093, France
    Recruiting
  • Novartis Investigative Site
    Paris, 75013, France
    Recruiting
  • Novartis Investigative Site
    Rennes, 35033, France
    Recruiting
  • Novartis Investigative Site
    Toulouse, 31059, France
    Recruiting
  • Novartis Investigative Site
    Munich, Bavaria 81377, Germany
    Recruiting
  • Novartis Investigative Site
    Würzburg, Bavaria 97080, Germany
    Recruiting
  • Novartis Investigative Site
    Bonn, North Rhine-Westphalia 53127, Germany
    Recruiting
  • Novartis Investigative Site
    Düsseldorf, North Rhine-Westphalia 40225, Germany
    Recruiting
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
    Recruiting
  • Novartis Investigative Site
    Leipzig, Saxony 04103, Germany
    Recruiting
  • Novartis Investigative Site
    Beelitz, 14547, Germany
    Recruiting
  • Novartis Investigative Site
    Berlin, 13353, Germany
    Recruiting
  • Novartis Investigative Site
    Stadtroda, 07646, Germany
    Recruiting
  • Novartis Investigative Site
    Tübingen, 72076, Germany
    Recruiting
  • Klinik für Neurologie (Schwerpunkt Neurodegeneration)
    Ulm, 89081, Germany
    Recruiting
  • Novartis Investigative Site
    Genova, GE 16132, Italy
    Recruiting
  • Novartis Investigative Site
    Milan, MI 20133, Italy
    Recruiting
  • Novartis Investigative Site
    Padova, PD 35128, Italy
    Recruiting
  • Novartis Investigative Site
    Roma, RM 00168, Italy
    Recruiting
  • Novartis Investigative Site
    Salerno, SA 84131, Italy
    Recruiting
  • Novartis Investigative Site
    Nagoya, Aichi-ken 4650065, Japan
    Recruiting
  • Novartis Investigative Site
    Gifu, Gifu 5011194, Japan
    Recruiting
  • Novartis Investigative Site
    Bunkyo Ku, Tokyo 1138431, Japan
    Recruiting
  • Novartis Investigative Site
    Kodaira, Tokyo 1878551, Japan
    Recruiting
  • Novartis Investigative Site
    Yonago, Tottori 6838504, Japan
    Recruiting
  • Novartis Investigative Site
    Rotterdam, South Holland 3015 GD, Netherlands
    Recruiting
  • Novartis Investigative Site
    Nijmegen, 6525 GA, Netherlands
    Recruiting
  • Novartis Investigative Site
    Seoul, 03722, South Korea
    Recruiting
  • Novartis Investigative Site
    Sant Cugat Del V, Barcelona 08190, Spain
    Recruiting
  • Novartis Investigative Site
    Pozuelo de Alarcón, Madrid 28223, Spain
    Recruiting
  • Novartis Investigative Site
    Barcelona, 08036, Spain
    Recruiting
  • Novartis Investigative Site
    Barcelona, 08041, Spain
    Recruiting
  • Novartis Investigative Site
    Las Palmas GC, 35010, Spain
    Recruiting
  • Novartis Investigative Site
    Madrid, 28009, Spain
    Recruiting
  • Novartis Investigative Site
    Madrid, 28034, Spain
    Recruiting
  • Novartis Investigative Site
    Madrid, 28041, Spain
    Recruiting
  • Novartis Investigative Site
    Seville, 41013, Spain
    Recruiting
  • Novartis Investigative Site
    Cambridge, CB2 0QQ, United Kingdom
    Recruiting
  • Novartis Investigative Site
    London, WC1N 3BG, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Jul 2029, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Mar 27, 2026
StartActual
Jun 3, 2026
Primary completionEst.
Jul 20, 2029
CompletionEst.
Jul 18, 2031
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
22 sites added — first sites in Belgium and United Kingdom
Show 22 added (5 China, 4 United States, 4 Japan, 3 Italy, 2 Belgium, 2 United Kingdom, 1 Australia, 1 Spain)
  • Parkinsons Disease and Movement Disorders Center of Boca Raton · Boca Raton, United States
  • University of Kentucky - C201 Clinic · Lexington, United States
  • Ochsner Clinic Foundation · New Orleans, United States
  • Central TX Neuro Consultants P A · Round Rock, United States
  • Novartis Investigative Site · Kogarah, Australia
  • Novartis Investigative Site · Leuven, Belgium
  • Novartis Investigative Site · Bruges, Belgium
  • Novartis Investigative Site · Chengdu, China
  • Novartis Investigative Site · Beijing, China
  • Novartis Investigative Site · Beijing, China
  • Novartis Investigative Site · Jinan, China
  • Novartis Investigative Site · Wuhan, China
  • Novartis Investigative Site · Genova, Italy
  • Novartis Investigative Site · Padova, Italy
  • Novartis Investigative Site · Salerno, Italy
  • Novartis Investigative Site · Nagoya, Japan
  • Novartis Investigative Site · Gifu, Japan
  • Novartis Investigative Site · Bunkyo Ku, Japan
  • Novartis Investigative Site · Yonago, Japan
  • Novartis Investigative Site · Sant Cugat Del V, Spain
  • Novartis Investigative Site · Cambridge, United Kingdom
  • Novartis Investigative Site · London, United Kingdom
Oct 15, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Mayo Clinic Arizona · Scottsdale, United StatesContact •••8300→•••8300
  • CenExcel Rocky Mtn Clin Research · Englewood, United StatesContact •••6674→•••6674
  • Mayo Jacksonville · Jacksonville, United StatesContact •••2254→•••2254
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    22 sites added — first sites in Belgium and United Kingdom
    Show 22 added (5 China, 4 United States, 4 Japan, 3 Italy, 2 Belgium, 2 United Kingdom, 1 Australia, 1 Spain)
    • Parkinsons Disease and Movement Disorders Center of Boca Raton · Boca Raton, United States
    • University of Kentucky - C201 Clinic · Lexington, United States
    • Ochsner Clinic Foundation · New Orleans, United States
    • Central TX Neuro Consultants P A · Round Rock, United States
    • Novartis Investigative Site · Kogarah, Australia
    • Novartis Investigative Site · Leuven, Belgium
    • Novartis Investigative Site · Bruges, Belgium
    • Novartis Investigative Site · Chengdu, China
    • Novartis Investigative Site · Beijing, China
    • Novartis Investigative Site · Beijing, China
    • Novartis Investigative Site · Jinan, China
    • Novartis Investigative Site · Wuhan, China
    • Novartis Investigative Site · Genova, Italy
    • Novartis Investigative Site · Padova, Italy
    • Novartis Investigative Site · Salerno, Italy
    • Novartis Investigative Site · Nagoya, Japan
    • Novartis Investigative Site · Gifu, Japan
    • Novartis Investigative Site · Bunkyo Ku, Japan
    • Novartis Investigative Site · Yonago, Japan
    • Novartis Investigative Site · Sant Cugat Del V, Spain
    • Novartis Investigative Site · Cambridge, United Kingdom
    • Novartis Investigative Site · London, United Kingdom
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Mayo Clinic Arizona · Scottsdale, United StatesContact •••8300→•••8300
    • CenExcel Rocky Mtn Clin Research · Englewood, United StatesContact •••6674→•••6674
    • Mayo Jacksonville · Jacksonville, United StatesContact •••2254→•••2254
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07498426
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Jun 3, 2026
Primary completion
Jul 20, 2029 (estimated)
Completion
Jul 18, 2031 (estimated)
Last update
Oct 15, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion